Interaction of antibodies with ErbB receptor extracellular regions

Experimental Cell Research

Volumn 315, Issue 4, 2009, Pages 659-670

  Schmitz, Karl R ^a   Ferguson, Kathryn M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antibody; Cetuximab Erbitux; EGFR ErbB1; Erbb receptor inhibition; Erbb2 HER2; Trastuzumab Herceptin

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PERTUZUMAB; TRASTUZUMAB;

CHEMISTRY; DIMERIZATION; DRUG EFFECT; HUMAN; METABOLISM; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DIMERIZATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; RECEPTOR, ERBB-2;

EID: 62649134382     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.10.008     Document Type: Review

References (105)

1. Y. Yarden, J. Schlessinger, Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor, Biochemistry 26 (1987) 1443-1451.
2. F. Bellot,W. Moolenaar, R. Kris, B. Mirakhur, I. Verlaan, A. Ullrich, J. Schlessinger, S. Felder, High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses, J. Cell Biol. 110 (1990) 491-502.
3. L.H. Defize, J. Boonstra, J. Meisenhelder,W. Kruijer, L.G. Tertoolen, B.C. Tilly, T. Hunter, P.M. van Bergen en Henegouwen, W.H. Moolenaar, S.W. de Laat, Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors, J. Cell Biol. 109 (1989) 2495-2507.
4. J.A. Drebin, D.F. Stern, V.C. Link, R.A. Weinberg, M.I. Greene, Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene, Nature 312 (1984) 545-548.
5. A.L. Schechter, D.F. Stern, L. Vaidyanathan, S.J. Decker, J.A. Drebin, M.I. Greene, R.A. Weinberg, The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen, Nature 312 (1984) 513-516.
6. J.A. Drebin, V.C. Link, D.F. Stern, R.A. Weinberg, M.I. Greene, Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies, Cell 41 (1985) 697-706.
7. H. Zhang, A. Berezov, Q.Wang, G. Zhang, J. Drebin, R. Murali, M.I. Greene, ErbB receptors: from oncogenes to targeted cancer therapies, J. Clin. Invest. 117 (2007) 2051-2058.
8. M.D. Waterfield, E.L. Mayes, P. Stroobant, P.L. Bennet, S. Young, P.N. Goodfellow, G.S. Banting, B. Ozanne, A monoclonal antibody to the human epidermal growth factor receptor, J. Cell. Biochem. 20 (1982) 149-161.
9. A.B. Schreiber, I. Lax, Y. Yarden, Z. Eshhar, J. Schlessinger, Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor, Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 7535-7539.
10. A.B. Schreiber, T.A. Libermann, I. Lax, Y. Yarden, J. Schlessinger, Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies, J. Biol. Chem. 258 (1983) 846-853.
11. G.N. Gill, T. Kawamoto, C. Cochet, A. Le, J.D. Sato, H. Masui, C. McLeod, J. Mendelsohn, Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity, J. Biol. Chem. 259 (1984) 7755-7760.
12. J.D. Sato, T. Kawamoto, A.D. Le, J. Mendelsohn, J. Polikoff, G.H. Sato, Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors, Mol. Biol. Med. 1 (1983) 511-529.
13. A. De Luca, A. Carotenuto, A. Rachiglio, M. Gallo, M.R. Maiello, D. Aldinucci, A. Pinto, N. Normanno, The role of the EGFR signaling in tumor microenvironment, J. Cell. Physiol. 214 (2008) 559-567.
14. N.E. Hynes, H.A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354.
15. J. Baselga, C.L. Arteaga, Critical update and emerging trends in epidermal growth factor receptor targeting in cancer, J. Clin. Oncol. 23 (2005) 2445-2459.
16. J. Mendelsohn, J. Baselga, Epidermal growth factor receptor targeting in cancer, Semin. Oncol. 33 (2006) 369-385.
17. N. Normanno, A. De Luca, C. Bianco, L. Strizzi, M. Mancino, M.R. Maiello, A. Carotenuto, G. De Feo, F. Caponigro, D.S. Salomon, Epidermal growth factor receptor (EGFR) signaling in cancer, Gene 366 (2006) 2-16.
18. H.M. Shepard, P. Jin, D.J. Slamon, Z. Pirot, D.C. Maneval, Herceptin, Handb. Exp. Pharmacol. (2008) 183-219.
19. A.W. Burgess, H.S. Cho, C. Eigenbrot, K.M. Ferguson, T.P. Garrett, D.J. Leahy, M.A. Lemmon, M.X. Sliwkowski, C.W. Ward, S. Yokoyama, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors, Mol. Cell 12 (2003) 541-552.
20. K.M. Ferguson, A structure-based view of Epidermal Growth Factor Receptor regulation, Ann. Rev. Biophys. 37 (2008) 353-373.
21. D.J. Leahy, Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors, Adv. Protein Chem. 68 (2004) 1-27.
22. M.A. Lemmon, Ligand-induced ErbB receptor dimerization, Exp. Cell Res. 315 (2009) 638-648.
23. S. Bouyain, P.A. Longo, S. Li, K.M. Ferguson, D.J. Leahy, The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand, Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 15024-15029.
24. H.S. Cho, D.J. Leahy, Structure of the extracellular region of HER3 reveals an interdomain tether, Science 297 (2002) 1330-1333.
25. K.M. Ferguson, M.B. Berger, J.M. Mendrola, H.S. Cho, D.J. Leahy, M.A. Lemmon, EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization, Mol. Cell 11 (2003) 507-517.
26. T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, G.O. Lovrecz, H.J. Zhu, F.Walker, M.J. Frenkel, P.A. Hoyne, R.N. Jorissen, E.C. Nice, A.W. Burgess, C.W. Ward, Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha, Cell 110 (2002) 763-773.
27. H. Ogiso, R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, J.H. Kim, K. Saito, A. Sakamoto, M. Inoue, M. Shirouzu, S. Yokoyama, Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains, Cell 110 (2002) 775-787.
28. H.S. Cho, K. Mason, K.X. Ramyar, A.M. Stanley, S.B. Gabelli, D.W. Denney Jr., D.J. Leahy, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature 421 (2003) 756-760.
29. T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, G.O. Lovrecz, M. Kofler, R.N. Jorissen, E.C. Nice, A.W. Burgess, C.W. Ward, The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors, Mol. Cell 11 (2003) 495-505.
30. T. Kawamoto, J.D. Sato, A. Le, J. Polikoff, G.H. Sato, J. Mendelsohn, Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody, Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 1337-1341.
31. H. Masui, T. Kawamoto, J.D. Sato, B. Wolf, G. Sato, J. Mendelsohn, Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies, Cancer Res. 44 (1984) 1002-1007.
32. J. Mendelsohn, Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications. Trans. Am. Clin. Climatol. Assoc. 100 (1988) 31-38.
33. N.I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, J. Mendelsohn, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model, Clin. Cancer Res. 1 (1995) 1311-1318.
34. R.I. Haddad, D.M. Shin, Recent advances in head and neck cancer, N. Engl. J. Med. 359 (2008) 1143-1154.
35. S.K. Blick, L.J. Scott, Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer, Drugs 67 (2007) 2585-2607.
36. E. Friedlander, M. Barok, J. Szollosi, G. Vereb, ErbB-directed immunotherapy: antibodies in current practice and promising new agents, Immunol. Lett. 116 (2008) 126-140.
37. U. Murthy, A. Basu, U. Rodeck, M. Herlyn, A.H. Ross, M. Das, Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide, Arch. Biochem. Biophys. 252 (1987) 549-560.
38. U. Rodeck, N. Williams, U. Murthy, M. Herlyn, Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha, J. Cell. Biochem. 44 (1990) 69-79.
39. J.H. Schiller, Developments in epidermal growth factor receptortargeting therapy for solid tumors: focus on matuzumab (EMD 72000), Cancer Invest. 26 (2008) 81-95.
40. M.V. Seiden, H.A. Burris, U. Matulonis, J.B. Hall, D.K. Armstrong, J. Speyer, J.D. Weber, F. Muggia, A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies, Gynecol. Oncol. 104 (2007) 727-731.
41. H.J. de Haard, N. van Neer, A. Reurs, S.E. Hufton, R.C. Roovers, P. Henderikx, A.P. de Bruine, J.W. Arends, H.R. Hoogenboom, A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies, J. Biol. Chem. 274 (1999) 18218-18230.
42. D. Lu, H. Zhang, D. Ludwig, A. Persaud, X. Jimenez, D. Burtrum, P. Balderes, M. Liu, P. Bohlen, L. Witte, Z. Zhu, Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody, J. Biol. Chem. 279 (2004) 2856-2865.
43. M. Liu, H. Zhang, X. Jimenez, D.L. Ludwig, L. Witte, P. Bohlen, D.J. Hicklin, Z. Zhu, Identification and characterization of a fully human antibody directed against epidermal growth factor receptor for cancer therapy, AACR Meeting Abstracts 2004 (2004) 163-c.
44. D. Lu, H. Zhang, H. Koo, J. Tonra, P. Balderes, M. Prewett, E. Corcoran, V. Mangalampalli, R. Bassi, D. Anselma, D. Patel, X. Kang, D.L. Ludwig, D.J. Hicklin, P. Bohlen, L. Witte, Z. Zhu, A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity, J. Biol. Chem. 280 (2005) 19665-19672.
45. M. Prewett, J.R. Tonra, B. Rajiv, A.T. Hooper, G. Makhoul, B. Finnerty, L. Witte, P. Bohlen, Z. Zhu, D.J. Hicklin, Antitumor activity of a novel, human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (IMC-11F8) in human tumor xenograft models, AACR Meeting Abstracts 2004 (2004) 1235.
46. B. Kuenen, E. Witteveen, R. Ruijter, A. Ervin-Haynes, M. Tjin-A-ton, F. Fox, C. Ding, G. Giaccone, E.E. Voest, A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results. J. Clin. Oncol. 24 (2006) 3024.
47. N. Lonberg, Human antibodies from transgenic animals, Nat. Biotechnol. 23 (2005) 1117-1125.
48. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang, C.G. Davis, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy, Crit. Rev. Oncol. Hematol. 38 (2001) 17-23.
49. M. Wu, A. Rivkin, T. Pham, Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer, Clin. Ther. 30 (2008) 14-30.
50. A. Iannello, A. Ahmad, Role of antibody-dependent cellmediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies, Cancer Metastasis Rev. 24 (2005) 487-499.
51. M. Peipp, M. Dechant, T. Valerius, Effector mechanisms of therapeutic antibodies against ErbB receptors, Curr. Opin. Immunol. 20 (2008) 436-443.
52. W.K. Bleeker, J.J. Lammerts van Bueren, H.H. van Ojik, A.F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M.A. van Dijk, J.G. van de Winkel, P.W. Parren, Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy, J. Immunol. 173 (2004) 4699-4707.
53. S.R. Ruuls, J.J. Lammerts van Bueren, J.G. van de Winkel, P.W. Parren, Novel human antibody therapeutics: the age of the Umabs, Biotechnol. J. (2008).
54. E. Aboud-Pirak, E. Hurwitz, M.E. Pirak, F. Bellot, J. Schlessinger, M. Sela, Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice, J. Natl. Cancer Inst. 80 (1988) 1605-1611.
55. L.H. Defize, W.H. Moolenaar, P.T. van der Saag, S.W. de Laat, Dissociation of cellular responses to epidermal growth factor using anti-receptor monoclonal antibodies, EMBO J. 5 (1986) 1187-1192.
56. K. Mishima, T.G. Johns, R.B. Luwor, A.M. Scott, E. Stockert, A.A. Jungbluth, X.D. Ji, P. Suvarna, J.R. Voland, L.J. Old, H.J. Huang,W.K. Cavenee, Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor, Cancer Res. 61 (2001) 5349-5354.
57. C.T. Kuan, C.J. Wikstrand, D.D. Bigner, EGF mutant receptor vIII as a molecular target in cancer therapy, Endocr. Relat. Cancer 8 (2001) 83-96.
58. A.A. Jungbluth, E. Stockert, H.J. Huang, V.P. Collins, K. Coplan, K. Iversen, D. Kolb, T.J. Johns, A.M. Scott, W.J. Gullick, G. Ritter, L. Cohen, M.J. Scanlan, W.K. Cavenee, L.J. Old, A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor, Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 639-644.
59. A.M. Scott, F.T. Lee, N. Tebbutt, R. Herbertson, S.S. Gill, Z. Liu, E. Skrinos, C. Murone, T.H. Saunder, B. Chappell, A.T. Papenfuss, A. M. Poon, W. Hopkins, F.E. Smyth, D. MacGregor, L.M. Cher, A.A. Jungbluth, G. Ritter, M.W. Brechbiel, R. Murphy, A.W. Burgess, E. W. Hoffman, T.G. Johns, L.J. Old, A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors, Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 4071-4076.
60. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, W.L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1987) 177-182.
61. B.M. Fendly, M. Winget, R.M. Hudziak, M.T. Lipari, M.A. Napier, A. Ullrich, Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product, Cancer Res. 50 (1990) 1550-1558.
62. D.B. Agus, R.W. Akita, W.D. Fox, G.D. Lewis, B. Higgins, P.I. Pisacane, J.A. Lofgren, C. Tindell, D.P. Evans, K. Maiese, H.I. Scher, M.X. Sliwkowski, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth, Cancer Cell 2 (2002) 127-137.
63. M.C. Franklin, K.D. Carey, F.F. Vajdos, D.J. Leahy, A.M. de Vos, M.X. Sliwkowski, Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex, Cancer Cell 5 (2004) 317-328.
64. S. Li, P. Kussie, K.M. Ferguson, Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8, Structure 16 (2008) 216-227.
65. S. Li, K.R. Schmitz, P.D. Jeffrey, J.J. Wiltzius, P. Kussie, K.M. Ferguson, Structural basis for inhibition of the epidermal growth factor receptor by cetuximab, Cancer Cell 7 (2005) 301-311.
66. J. Schmiedel, A. Blaukat, S. Li, T. Knochel, K.M. Ferguson, Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization, Cancer Cell 13 (2008) 365-373.
67. D. Freeman, J. Sun, R. Bass, K. Jung, S. Ogbagabriel, G. Elliot, R. Radinsky, Panitumumab and cetuximab epitope mapping and in vitro activity. Clin. Oncol. 26 (2008) A14536.
68. J.J. Lammerts van Bueren, W.K. Bleeker, A. Brannstrom, A. von Euler, M. Jansson, M. Peipp, T. Schneider-Merck, T. Valerius, J.G. van de Winkel, P.W. Parren, The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 6014-6109.
69. M. Dechant, W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J.J. Lammerts van Bueren, W.K. Bleeker, P.W. Parren, J.G. van de Winkel, T. Valerius, Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies, Cancer Res. 68 (2008) 4998-5003.
70. J.P. Dawson, M.B. Berger, C.C. Lin, J. Schlessinger, M.A. Lemmon, K.M. Ferguson, Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface, Mol. Cell. Biol. 25 (2005) 7734-7742.
71. J.P. Dawson, Z. Bu, M.A. Lemmon, Ligand-induced structural transitions in ErbB receptor extracellular domains. Structure 15 (2007) 942-954.
72. K.M. Ferguson, P.J. Darling, M.J. Mohan, T.L. Macatee, M.A. Lemmon, Extracellular domains drive homo- but not hetero-dimerization of erbB receptors, EMBO J. 19 (2000) 4632-4643.
73. T.S. Wehrman, W.J. Raab, C.L. Casipit, R. Doyonnas, J.H. Pomerantz, H.M. Blau, A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions, Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 19063-19068.
74. M.A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, J. Baselga, Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells, Cancer Res. 61 (2001) 4744-4749.
75. E. Greenebaum, M. Nicolaides, M. Eisinger, R.H. Vogel, I.B. Weinstein, Binding of phorbol dibutyrate and epidermal growth factor to cultured human epidermal cells, J. Natl. Cancer Inst. 70 (1983) 435-441.
76. W.J. Gullick, D.J. Downward, J.J. Marsden, M.D. Waterfield, A radioimmunoassay for human epidermal growth factor receptor, Anal. Biochem. 141 (1984) 253-261.
77. C. Wofsy, B. Goldstein, K. Lund, H.S. Wiley, Implications of epidermal growth factor (EGF) induced egf receptor aggregation, Biophys. J. 63 (1992) 98-110.
78. J.L. Macdonald, L.J. Pike, Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 112-117.
79. A. Ullrich, J. Schlessinger, Signal transduction by receptors with tyrosine kinase activity, Cell 61 (1990) 203-212.
80. P. Klein, D. Mattoon, M.A. Lemmon, J. Schlessinger, A structure-based model for ligand binding and dimerization of EGF receptors, Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 929-934.
81. D. Mattoon, P. Klein, M.A. Lemmon, I. Lax, J. Schlessinger, The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function, Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 923-928.
82. F. Walker, S.G. Orchard, R.N. Jorissen, N.E. Hall, H.H. Zhang, P.A. Hoyne, T.E. Adams, T.G. Johns, C. Ward, T.P. Garrett, H.J. Zhu, M. Nerrie, A.M. Scott, E.C. Nice, A.W. Burgess, CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor, J. Biol. Chem. 279 (2004) 22387-22398.
83. T.G. Johns, T.E. Adams, J.R. Cochran, N.E. Hall, P.A. Hoyne, M.J. Olsen, Y.S. Kim, J. Rothacker, E.C. Nice, F. Walker, G. Ritter, A.A. Jungbluth, L.J. Old, C.W. Ward, A.W. Burgess, K.D. Wittrup, A.M. Scott, Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor, J. Biol. Chem. 279 (2004) 30375-30384.
84. G. Chao, J.R. Cochran, K.D. Wittrup, Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display, J. Mol. Biol. 342 (2004) 539-550.
85. T.G. Johns, E. Stockert, G. Ritter, A.A. Jungbluth, H.J. Huang, W.K. Cavenee, F.E. Smyth, C.M. Hall, N. Watson, E.C. Nice, W.J. Gullick, L.J. Old, A.W. Burgess, A.M. Scott, Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene, Int. J. Cancer 98 (2002) 398-408.
86. A. Sivasubramanian, G. Chao, H.M. Pressler, K.D. Wittrup, J.J. Gray, Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis, Structure 14 (2006) 401-414.
87. M.V. Karamouzis, F.A. Badra, A.G. Papavassiliou, Breast cancer: the upgraded role of HER-3 and HER-4, Int. J. Biochem. Cell Biol. 39 (2007) 851-856.
88. D.L. Wheeler, V.M. Rangnekar, S.R. Schwarze, ErbB4 targeting approaches for prostate cancer treatment, Cancer Biol. Ther. 7 (2008) 1095-1097.
89. G. Sithanandam, L.M. Anderson, The ERBB3 receptor in cancer and cancer gene therapy, Cancer Gene Ther. 15 (2008) 413-448.
90. A. Vexler, G. Lidawi, V. Loew, I. Barnea, V. Karaush, S. Lev-Ari, A. Shtabsky, R. Ben-Yosef, Anti-ERBb4 targeted therapy combined with radiation therapy in prostate cancer. Results of in vitro and invivo studies, Cancer Biol. Ther. 7 (2008) 1090-1094.
91. L.M. Gilmour, K.G. Macleod, A. McCaig, J.M. Sewell, W.J. Gullick, J.F. Smyth, S.P. Langdon, Neuregulin expression, function, and signaling in human ovarian cancer cells, Clin. Cancer Res. 8 (2002) 3933-3942.
92. L.M. Friedman, A. Rinon, B. Schechter, L. Lyass, S. Lavi, S.S. Bacus, M. Sela, Y. Yarden, Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy, Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 1915-1920.
93. V. Kamat, J.M. Donaldson, C. Kari, M.R. Quadros, P.I. Lelkes, I. Chaiken, S. Cocklin, J.C. Williams, E. Papazoglou, U. Rodeck, Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425, Cancer Biol. Ther. 7 (2008) 726-733.
94. D. Lu, H. Zhang, H. Koo, J. Tonra, P. Balderes, M. Prewett, E. Corcoran, V. Mangalampalli, R. Bassi, D. Anselma, D. Patel, X. Kang, D.L. Ludwig, D.J. Hicklin, P. Bohlen, L. Witte, Z. Zhu, A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity, J. Biol. Chem. 280 (2005) 19665-19672.
95. M.B. Berger, J.M. Mendrola, M.A. Lemmon, ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface, FEBS Lett. 569 (2004) 326-332.
96. I. Lax, R. Fischer, C. Ng, J. Segre, A. Ullrich, D. Givol, J. Schlessinger, Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity, Cell Regul. 2 (1991) 337-345.
97. M.E. Winkler, L. O, Connor, M. Winget, B. Fendly, Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor, Biochemistry 28 (1989) 6373-6378.
98. H.C. Gooi, E.F. Hounsell, I. Lax, R.M. Kris, T.A. Libermann, J. Schlessinger, J.D. Sato, T. Kawamoto, J. Mendelsohn, T. Feizi, The carbohydrate specificities of the monoclonal antibodies 29.1, 455 and 3C1B12 to the epidermal growth factor receptor of A431 cells, Biosci. Rep. 5 (1985) 83-94.
99. J. Schlessinger, I. Lax, Y. Yarden, H. Kanety, T.A. Libermann, Monoclonal Antibodies to Receptors, in: M.F. Greaves (Ed.), Receptors and Recognition, 17, Chapman and Hall, London, 1984, pp. 279-303.
100. Y. Yarden, I. Harari, J. Schlessinger, Purification of an active EGF receptor kinase with monoclonal antireceptor antibodies, J. Biol. Chem. 260 (1985) 315-319.
101. C.W. Reuter, M.A. Morgan, A. Eckardt, Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck, Br. J. Cancer 96 (2007) 408-416.
102. A. Fernandez, E. Spitzer, R. Perez, F.D. Boehmer, K. Eckert, W. Zschiesche, R. Grosse, A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections, J. Cell. Biochem. 49 (1992) 157-165.
103. H. Modjtahedi, D.K. Moscatello, G. Box, M. Green, C. Shotton, D.J. Lamb, L.J. Reynolds, A.J. Wong, C. Dean, H. Thomas, S. Eccles, Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy, Int. J. Cancer 105 (2003) 273-280.
104. H. Modjtahedi, J.M. Styles, C.J. Dean, The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468, Br. J. Cancer 67 (1993) 247-253.
105. R.M. Hudziak, G.D. Lewis, M. Winget, B.M. Fendly, H.M. Shepard, A. Ullrich, p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor, Mol. Cell. Biol. 9 (1989) 1165-1172.